HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) (350837)

    From US Department of Health & Human Services: National Institutes of Health (NIH)

    The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.

    Type of Support

    Overview

    This funding opportunity announcement (FOA) aims to support the preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The overarching goal is to accelerate the optimization and development of promising small molecule and biologic hits/leads towards clinical trials. The program focuses on optimizing and developing potential treatments, conducting IND-enabling studies, and preparing for Investigational New Drug (IND) application submissions. It is a phased cooperative agreement that requires the participation of NIH program staff in planning and progress monitoring. Applicants are expected to have a promising hit/lead, a robust biological rationale for their approach, and identified assays for agent optimization.

    Eligibility

    Organization's Location
    ad id
    Program Location
    et proident aute irure dolore velit aliquip laboris labore laboris
    Organization Type
    not specified

    Submission

    Visit Apply for more information.

    Similar grants